Vafseo (vadadustat) for anemia in CKD on dialysis
Customize your policy alerts
Sign up for Cigna Policy IP0706 alerts
Get alerted when Policy IP0706 changes without checking for updates manually.
Monitor payer policy activity
This coverage policy governs prior authorization and medical necessity criteria for Vafseo (vadadustat tablets) for treatment of anemia due to chronic kidney disease in adults receiving dialysis, and describes excluded uses. It applies to Cigna-administered health benefit plans as detailed in the policy.
No material clinical or coverage changes in this revision.
OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.